Leerink Partners analyst Marc Goodman reiterated a Buy rating on Neurocrine (NBIX – Research Report) on May 5 and set a price target of $160.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Marc Goodman has given his Buy rating due to a combination of factors that highlight Neurocrine’s positive outlook. The company’s recent financial performance, particularly the first quarter of 2025, showed promising results with Ingrezza sales aligning with expectations and a record number of new patient starts, driven by an expanded sales force and direct-to-consumer campaign. Additionally, Crenessity’s sales exceeded forecasts, contributing to the stock’s post-market rise.
Furthermore, Neurocrine’s pipeline is advancing well, with several Phase 3 trials underway and anticipated data releases for other promising treatments later in the year. The company’s strategic moves, such as increased Part D coverage for Ingrezza, are expected to positively impact sales. These developments, along with management’s reaffirmed spending guidance, support the reiterated price target and Outperform rating, reinforcing investor confidence in the stock.
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $160.00 price target.
NBIX’s price has also changed slightly for the past six months – from $121.530 to $109.750, which is a -9.69% drop .